What Prolutex Treats: Main Uses and Benefits

Prolutex is commonly used in clinical settings that involve Assisted Reproductive Technology (ART) cycles, such as in vitro fertilization (IVF). This medicine is relevant when supportive symptom management is appropriate to address situations of hormonal need. The primary therapeutic domains include situations involving certain distressing symptoms associated with early pregnancy support and addressing systemic imbalance.

This therapy is applied in scenarios where additional management of discomfort is required to sustain the necessary physiological environment post-embryo transfer, which assists with maintaining functional stability during the treatment process. The medication plays a role in managing conditions linked to systemic imbalance.

Quick Fact: Relief for Symptoms related to Systemic Imbalance

The medication is applied in addressing symptoms related to systemic imbalance, which contributes to improved comfort during periods of heightened symptoms. “It helps maintain a sense of stability when symptoms are more noticeable and contributes to easing the overall symptom load during the critical early weeks.” This targeted support may be part of symptomatic management that supports embryo attachment.

Regulatory References

1. Therapeutic Goods Administration of Australia (TGA)

Population Eligibility and Non-Eligibility

The regulatory use of Prolutex is strictly confined to adult women of child-bearing age receiving luteal phase support as part of an Assisted Reproductive Technology (ART) treatment program, typically until 12 weeks of confirmed pregnancy. Eligibility is precisely defined by regulatory exclusions and prohibitions.

Absolute Contraindications

Official labeling prohibits use in individuals with conditions such as severe hepatic dysfunction or disease, known or suspected cancer of the breast or genital tract, and current or historical diagnosis of active arterial or venous thromboembolism or severe thrombophlebitis. Use is also forbidden in cases of undiagnosed vaginal bleeding, known missed abortion, Porphyria, or a history of specific conditions during pregnancy, such as idiopathic jaundice.

Restricted and Non-Established Use

Use is not established and considered not appropriate for the pediatric (0–18 years) and elderly (over 65 years) populations. The medicine should not be used by women who are breastfeeding. Conditional restrictions require close observation and caution for patients with mild to moderate hepatic or renal dysfunction, a history of depression, or conditions influenced by fluid retention like epilepsy or cardiac dysfunction.

Interactions with other medicines and products

The interaction profile for Prolutex is formally defined by its pharmacokinetic constraints relating to the hepatic CYP450 3A4 enzyme system and specific administration rules documented in regulatory sources.

---

Pharmacokinetic Interactions

The co-administration of Prolutex with certain other medicines may alter the concentration of Progesterone in the body:

• Exposure-Decreasing Substances: Medicines that are strong inducers of the CYP3A4 system—such as Rifampicin, Phenytoin, Carbamazepine, Phenobarbital, and Griseofulvin—may accelerate the elimination of Progesterone, leading to decreased bioavailability. The herbal product St. John's Wort is also documented as having this induction effect.

• Exposure-Increasing Substances: Conversely, strong inhibitors of the CYP3A4 system, such as Ketoconazole, may decrease the elimination rate of Progesterone, resulting in increased plasma concentrations.

---

Interactions Affecting Other Medicines

• Ciclosporin: Progesterone can inhibit the metabolism of the immunosuppressant Ciclosporin, which may lead to increased plasma concentrations of Ciclosporin and a potential risk of toxicity.

Administration and Pharmacodynamic Constraints

• Antidiabetic Agents: Because Progesterone may influence diabetic control, patients using Antidiabetic Medicines may require an observation or adjustment to the dosage of their antidiabetic therapy.
• Other Injections: Prolutex must not be administered at the same time (concomitant use is not recommended) as any other injectable medicine.
• Alcohol: Consumption of alcohol may worsen the central nervous system effects, such as dizziness or drowsiness, associated with the medication.

Prolutex is a pharmaceutical preparation of progesterone, which functions as an agonist of the nuclear progesterone receptor (PR). After crossing the cell membrane, progesterone binds to the cytoplasmic PR isoforms, primarily PR-A and PR-B. This ligand-binding induces a conformational change in the receptor, leading to dissociation from chaperone proteins, subsequent dimerization, and translocation of the complex into the cell nucleus.

In the nucleus, the activated receptor dimer acts as a ligand-activated transcription factor, binding to specific DNA sequences known as Progesterone Response Elements (PREs) in the promoter regions of target genes. This binding modulates the recruitment of coactivator and corepressor molecules, leading to the initiation or repression of gene transcription and subsequent protein synthesis. The downstream consequences include a shift in target tissues, such as the endometrium and myometrium, from a proliferative to a secretory and quiescent phenotype. This system-level modulation encompasses the inhibition of estrogen-driven cellular proliferation in the endometrium and the maintenance of a low-contractility state in the myometrium.

Dosing and Administration Guidelines

Administration of Prolutex (progesterone injection) follows standardized protocols for its use in Assisted Reproductive Technology (ART) protocols. The standard regimen requires the administration of a 25 mg dose of the sterile solution once daily. Treatment initiation is timed to begin on the day of oocyte retrieval.

---

Administration Routes and Settings

The medicine is used via two routes of parenteral administration, which dictate the setting of use:

• Subcutaneous (SC) Injection: This route may be self-administered by the patient following specialized training and advice from a healthcare professional. Rotation of the injection site is recommended for SC use to maintain procedural compliance.
• Intramuscular (IM) Injection: This route must be performed by a doctor or qualified healthcare professional.

Course Duration and Procedural Rules

The once-daily administration is continuous, lasting for up to 12 weeks of confirmed pregnancy. If a dose is missed, clinical guidance involves administering the dose as soon as possible and contacting a physician, while explicitly stating that the dose must not be doubled to compensate for the omission. The product is for single use only, and any residual solution must be discarded immediately after the required dose is delivered. Furthermore, there are no dosing instructions established for use in pediatric, elderly, or severely renally or hepatically impaired populations.

Research Evidence / Overview of Studies for Prolutex

---

Evidence for Use in Assisted Reproductive Technology (ART) Cycles

Prolutex was studied for its use in luteal phase support (LPS), a process relevant for women undergoing reproductive procedures like In Vitro Fertilization (IVF) and intracytoplasmic sperm injection (ICSI). The primary research involved several large-scale clinical trials known as Phase III Randomized Controlled Trials (RCTs). These studies included adult women (typically between 18 and 42 years old). The research setting was during controlled ovarian stimulation and subsequent embryo transfer.

These trials were designed to examine outcomes related to achieving and sustaining a pregnancy. Key measurements focused on the Ongoing Pregnancy Rate, which tracked pregnancy up to 10 to 12 weeks of gestation, and the Live Birth Rate. These outcomes track specific objectives within the treatment process. The research also examined biomarkers during this period, such as serum progesterone concentrations, which reflect hormonal activity.

The findings describe patterns observed in the studies where the subcutaneous formulation was compared to other established methods of progesterone support, such as vaginal gels or pessaries. The purpose of these comparisons was to examine whether the injectable preparation's measured outcomes fell within a defined range of the existing standard treatment, a study method known as non-inferiority. This research contributes to the broader evidence landscape by providing data on an alternative administration route for luteal phase support.

---

How Prolutex was Studied Against Existing Treatments

Clinical development focused on comparing Prolutex against standard forms of progesterone already in use, primarily vaginal progesterone preparations. The structure of these studies meant they were designed to see if the injection's primary measured outcomes were comparable to the vaginal products, rather than trying to demonstrate a superior result. The trials were open-label, meaning both the patients and the researchers knew which treatment was being administered, a design that may influence how certain outcomes were reported.

The primary outcomes examined in these comparative trials related to clinical measurements of a pregnancy, such as the initial Clinical Pregnancy Rate and the final Live Birth Rate. The findings help contextualize how patients reported their experience and how the administered hormone levels evolved in their systems. The research explored short-term changes in these rates during the crucial early weeks following embryo transfer, with treatment typically beginning on the day of oocyte retrieval.

---

Long-Term Outcomes and Follow-Up Data

The major research studies monitored the women and their pregnancies for a defined period that spanned the time of treatment up to 10 to 12 weeks of gestation. This duration allowed researchers to capture the primary endpoints, such as the Ongoing Pregnancy Rate and, subsequently, the Delivery Rate.

While the studies tracked the final delivery outcomes and confirmed the live birth of the infants, long-term effects are not fully established beyond that point. There is limited information for long-term outcomes regarding the reproductive and general health of the women who received the medication.

---

Evidence in Specific Patient Groups

The populations included in the core clinical trials were generally healthy adult women undergoing their ART cycle, with certain health and age criteria applied to ensure the study results were consistent. Therefore, results apply only to the populations studied in these specific research settings.

Data for certain groups remain insufficient. For instance, women with significant underlying health conditions (comorbidities) that might affect their treatment response were often excluded from the primary trials.

---

What is Still Uncertain About the Research

One key aspect is that the main studies were designed as non-inferiority trials, meaning they did not set out to demonstrate a superiority in outcomes over the established vaginal preparations. This distinction means the research does not provide a direct comparison to suggest one method achieves superior outcomes.

Furthermore, the open-label design of the pivotal trials is a recognized research limitation. Because both the patient and the clinician knew which drug was being administered, it may introduce non-treatment factors that influence reported measurements. The evidence base also includes limited information for long-term outcomes, meaning that tracking the health of mothers and children over many years following the use of the drug is not fully established by the primary regulatory research.

Key Studies & References

1. Prolutex 25 mg solution for injection: Summary of Product Characteristics (SPC) - Therapeutic Indications and Clinical Particulars

Common questions about Prolutex (FAQ)

---

Q: Is Prolutex the same as other progesterone injections I've heard about?

Prolutex is one specific formulation of progesterone for injection. Official information notes that it is prepared as an aqueous (water-based) solution for injection, which makes it technically distinct from certain older progesterone products that use an oil-based solution for administration.

---

Q: Does Prolutex contain peanut oil or sesame oil?

Prolutex is formulated as an aqueous (water-based) solution using a specific vehicle with cyclodextrins, unlike oil-based preparations. The official product documentation does not list common oils such as peanut oil or sesame oil as active excipients.

---

Q: What is the difference between Prolutex and oral progesterone pills?

The injectable form is studied to provide predictable and systemic progesterone concentrations in the bloodstream, meaning the hormone levels throughout the body are consistent. This method of delivery is described as differing from oral pills, which may have varying absorption and lower bioavailability (the rate at which the drug enters circulation).

---

Q: How long after starting Prolutex might I expect to feel different?

The full therapeutic level, known as steady state, is where the hormone concentration is consistent in the body. In clinical studies, this steady state is generally reached after approximately four days of daily subcutaneous use.

---

Q: What is the typical amount of time needed for the progesterone from Prolutex to leave the system?

Progesterone has a relatively short elimination time. The time it takes for half of the drug to be eliminated from the body, known as the terminal half-life, is documented as being around 13 to 14 hours for this hormone.

---

Q: Is Prolutex used for hormonal balancing in general?

Official regulatory documents strictly limit the approved use of Prolutex to providing luteal phase support for women undergoing an Assisted Reproductive Technology (ART) treatment program. It is not indicated for general hormonal balancing purposes outside of this specific approved use.

---

Q: Is it normal to feel a small lump at the injection site after using Prolutex?

Induration, which is the clinical term for a localized hardening or small lump, is listed in regulatory documents as a common injection site reaction. This is classified in the safety profile as a common injection site reaction.

---

Q: How quickly does the progesterone level increase after a Prolutex injection?

Clinical studies indicate that the subcutaneous injection is described as resulting in rapid absorption of the hormone. It is noted to achieve its peak concentration in the bloodstream more quickly compared to older oil-based progesterone preparations.

---

Q: Are there foods or drinks that should be avoided while using Prolutex?

The official product labeling identifies alcohol consumption as a point of caution. Additionally, official drug information warns that strong inhibitors of the CYP3A4 enzyme system may increase the progesterone concentration in the body. While certain foods like grapefruit juice are known inhibitors of this enzyme, they are not always explicitly listed in the regulatory documents.

---

Q: Is it possible to have an allergic reaction to Prolutex?

An allergic reaction to the medicine or its ingredients, including a severe hypersensitivity reaction, is possible. Regulatory information notes that symptoms such as hives, swelling of the face, or difficulty breathing are considered serious adverse reactions.

---

Q: Are there any long-term effects associated with Prolutex use mentioned in official sources?

The primary regulatory studies focused on outcomes up to the time of delivery and for a short period thereafter. Official documentation notes that there is limited information for long-term outcomes regarding the reproductive and general health of women and children beyond this study period.

---

Q: Can Prolutex cause stomach upset?

Gastrointestinal disturbances are classified as common side effects of the medicine. This group of effects includes symptoms such as nausea, abdominal pain, and may include general stomach upset.

---

Q: What are the signs of too much progesterone while using Prolutex?

Official warnings related to excessive exposure note that certain serious side effects like severe headache, signs of thromboembolic disorders (blood clots), or sudden changes in vision are documented events. These events are described as risks associated with this medication.

---

Q: Does Prolutex interact with grapefruit juice?

Official drug information warns that strong inhibitors of the CYP3A4 enzyme system may increase the progesterone concentration in the body. While grapefruit juice is a known inhibitor of this enzyme system, it is not always explicitly listed in the regulatory documents.

---

Q: Is Prolutex approved by the FDA?

Prolutex is known to be an investigational drug in the United States and has not received FDA approval under this name. The medicine is approved and available in many international markets.

---

Q: Does Prolutex have different brand names in other countries?

Yes, Prolutex is marketed in various countries under other brand names. These brand names may include Lubion®, Pleyris®, Progiron®, and Inprosub®.

---

Q: Can Prolutex be used alongside other hormone treatments?

Official guidance describes that the medicine is not recommended for administration at the same time (concomitantly) as any other injectable medicine. However, it is used in ART protocols that may involve other non-injectable hormone treatments, such as oral estrogen.

---

Q: Is Prolutex used to treat symptoms of menopause?

Official regulatory documents strictly limit the approved use of Prolutex to providing luteal phase support for women undergoing an Assisted Reproductive Technology (ART) treatment program. It is not approved for the treatment of menopausal symptoms.

---

Q: What class of drug does Prolutex belong to?

Prolutex belongs to the main pharmacological class of Exogenous Progestogens (Steroid Hormone). Its specific anatomical therapeutic chemical (ATC) classification is G03DA04 (progesterone), which is under the group for Sex Hormones and Modulators of the Genital System.

---

Q: Can Prolutex cause temporary changes in weight?

Official drug information includes weight gain in the list of general adverse reactions for progesterone injections. Caution is also advised for patients with conditions influenced by fluid retention.

Storage Requirements and Stability

Prolutex must be stored below a maximum temperature of 25, C and must be kept in its original packaging to protect it from light [1.1]. The medicine must also be protected from frost [1.1] and kept out of the sight and reach of children [1.3].

The Prolutex vial is intended for single-use only [1.3]. The solution must be used immediately after opening the vial, and any solution remaining afterward must be discarded and not stored for later use [1.3]. The product should not be used if it is past the expiry date or if the solution contains particles or appears cloudy [1.3].

Disposal Instructions

Official disposal guidelines mandate that all used injection materials, including needles, empty vials, and syringes, must be placed in a puncture-resistant sharps container [1.3]. Any unused product remaining in the vial must also be discarded [1.3]. Disposal of both the unused medicine and the sharps container must be performed according to local regulatory requirements [1.3].